Key Highlights
- McKesson slipped onto the list of the S&P 500's weaker stocks on Friday, with no company-specific news found, a day after rallying to $890.35 on news of an extended CVS Health distribution deal.
- The Thursday CVS extension runs through June 30, 2032, and McKesson reaffirmed its fiscal 2027 adjusted Earnings guidance of $44.20 to $45 per share alongside the announcement.
- Fellow distributors Cardinal Health and Cencora also fell Friday, placing all three on the list of S&P 500 laggards as health care became the only one of 11 sectors to close lower.
- The broader market rallied on a weak September jobs report, with investors pouring into growth names like Nvidia and Tesla while steadier, defensive businesses like drug distribution were not the focus.
McKesson (NYSE:MCK) handed back some of Thursday's gains on Friday, with no fresh news and health care lagging a market that was busy chasing chips. Shares slipped onto the list of the S&P 500's weaker stocks one day after a strong rally on a long-term contract extension with CVS Health. McKesson is the largest of the big three US drug wholesalers. It moves prescription medicines from manufacturers to pharmacies and health systems, and also runs businesses in specialty oncology care and medical-surgical supplies. No company-specific news on McKesson was found for Friday, and the decline was modest compared with the previous day's gain.
Thursday Set the Stage
On October 1, McKesson and Cardinal Health both said they had extended their distribution agreements with CVS Health through June 30, 2032. CVS is one of McKesson's most important customers, so the extension gives it visibility on that relationship for several more years.
McKesson stock rallied hard on the news, closing at $890.35. The company also reaffirmed its fiscal 2027 adjusted earnings guidance of $44.20 to $45 per share.
On Friday, McKesson slipped back. Cardinal Health and Cencora also fell, which put all three distributors among the S&P 500's laggards. A pullback after a sharp one-day jump is common, and nothing new surfaced to explain the move.
Health Care Fell Out of Favour
The broader backdrop did not help. Health care was the only one of the 11 S&P 500 sectors to finish lower on Friday, although its loss was tiny. Other health care names such as Veeva Systems and Boston Scientific were also down.
The day belonged to technology. The Labor Department said the US added just 29,000 jobs in September, far below the roughly 84,000 expected, with private payrolls up only 46,000. July was revised to a loss of 10,000 jobs.
That soft data dented expectations for another Federal Reserve rate hike. The Fed raised rates on September 16, its first increase since 2023, as an oil shock tied to the war with Iran pushed Inflation higher. After Friday's report, odds of another hike at the October 27-28 meeting dropped to roughly one in five.
Investors poured money into growth names: Nvidia hit a record high during the session, Tesla jumped on strong deliveries and the Nasdaq-100 set a record close. Steadier, defensive businesses like drug distribution were not the focus.
Steady Business, Shifting Mood
McKesson's Business tends to be less sensitive to economic swings than most. People need their medicines regardless of the jobs market, and health care was one of the stronger pockets of the September report, adding 17,000 jobs.
That stability is often prized when markets are nervous. On a day when traders were embracing risk, the stock's defensive appeal mattered less.
The Bond Market added a wrinkle. Treasury yields dipped after the jobs report but reversed to close higher, leaving the 10-year near its highest level since 2002.
The Reaffirmed Outlook Is the Benchmark
The reaffirmed fiscal 2027 outlook of $44.20 to $45 per share gives investors a clear marker for McKesson's next update. The extended CVS deal, running to mid-2032, is now part of that picture.
On the macro side, the Fed meets on October 27-28. Earnings season kicks off with PepsiCo on October 8, Delta on October 9 and the big banks on October 13 and 14. The near-term question for McKesson is whether Friday's slip was a one-day breather or the start of a broader cooling in the distribution group after Thursday's burst of enthusiasm.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...